These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A single (99m)Tc-MIBI study to predict response to neoadjuvant treatment in sarcoma patiens.
    Author: Sohaib M, Wiqar MA, Ali MK, Hussain F, Umer-i-Farooq.
    Journal: Hell J Nucl Med; 2011; 14(2):140-5. PubMed ID: 21761016.
    Abstract:
    Technetium-99m methoxy isobutyl isonitrile ((99m)Tc-MIBI) was used as a tumour imaging agent to predict the response of neoadjuvant treatment in patients with bone and soft tissue sarcoma. Our study included 31 patients (M:F = 23:8), 17 having osteosarcomas and 14 with soft-tissues sarcomas. Scintigraphy with (99m)Tc-MIBI was performed before the initiation of the neoadjuvant treatment. Static images were acquired at 10 and 60min post-injection and lesion to normal (L/N) ratios and washout rates (WR%) were calculated. Tumour response was assessed by detecting percent necrosis in a surgically resected specimen. Responses were correlated and compared with WR%. Percentage of tumour necrosis was 71.35±20.20% (mean±SD) with eight good and 23 poor responses. On visual analysis, 16 showed homogeneous, 11 heterogeneous and 4 doughnut shaped pattern of uptake. Seventy five percent of good responders had homogeneous uptake. Early and delayed L/N ratios were significantly different in both good and poor responders (P=0.006 and P<0.001, respectively) but correlated poorly with the tumour necrosis values in the specimen (R=0.23 and 0.06 respectively). Mean washout rate was 26.13±11.25% (median = 29%) and there was weak correlation between tumour necrosis and WR% (r=-0.32, P=0.029). The mean WR% of good responders was 15.0±10.0% and that of poor responders was significantly higher (30.1±8.8%, P=0.003). Good responders by 88% were below the median cut-of value. In conclusion WR% of (99m)Tc-MIBI may be used before surgery to identify poor responders to neoadjuvant treatment in patients with bone and soft tissue sarcomas.
    [Abstract] [Full Text] [Related] [New Search]